To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Entos Pharmaceuticals Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06436911
- Locations
- 🇨🇦
Diex Recherche Quebec, Québec, Quebec, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇨🇦Diex Recherche, Sherbrooke, Quebec, Canada
A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
Phase 1
Completed
- Conditions
- SARS-CoV-2
- Interventions
- Biological: Covigenix VAX-001Biological: Covigenix VAX-001 placebo
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Entos Pharmaceuticals Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT04591184
- Locations
- 🇿🇦
FARMOVS (PTY) Ltd., Bloemfontein, South Africa
🇧🇫National Center for Research and Training on Malaria, Ouagadougou, Burkina Faso
🇨🇦Canadian Centre for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada
© Copyright 2025. All Rights Reserved by MedPath